The average dividend yield in the S&P 500 Index remains low at around 1.3%. As a result, many stocks have lower dividend ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...

DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...

In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...